Literature DB >> 32124093

A Microfluidic Perfusion Platform for In Vitro Analysis of Drug Pharmacokinetic-Pharmacodynamic (PK-PD) Relationships.

Yadir A Guerrero1, Diti Desai1, Connor Sullivan1, Erick Kindt2, Mary E Spilker2, Tristan S Maurer3, Deepak E Solomon4, Derek W Bartlett5.   

Abstract

Static in vitro cell culture studies cannot capture the dynamic concentration profiles of drugs, nutrients, and other factors that cells experience in physiological systems. This limits the confidence in the translational relevance of in vitro experiments and increases the reliance on empirical testing of exposure-response relationships and dose optimization in animal models during preclinical drug development, introducing additional challenges owing to species-specific differences in drug pharmacokinetics (PK) and pharmacodynamics (PD). Here, we describe the development of a microfluidic cell culture device that enables perfusion of cells under 2D or 3D culture conditions with temporally programmable concentration profiles. Proof-of-concept studies using doxorubicin and gemcitabine demonstrated the ability of the microfluidic PK-PD device to examine dose- and time-dependent effects of doxorubicin as well as schedule-dependent effects of doxorubicin and gemcitabine combination therapy on cell viability using both step-wise drug concentration profiles and species-specific (i.e., mouse, human) drug PK profiles. The results demonstrate the importance of including physiologically relevant dynamic drug exposure profiles during in vitro drug testing to more accurately mimic in vivo drug effects, thereby improving translatability across nonclinical studies and reducing the reliance on animal models during drug development.

Entities:  

Keywords:  microfluidics; pharmacodynamics; pharmacokinetics; translational pharmacology

Mesh:

Substances:

Year:  2020        PMID: 32124093     DOI: 10.1208/s12248-020-0430-y

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  48 in total

Review 1.  Lost in translation: animal models and clinical trials in cancer treatment.

Authors:  Isabella Wy Mak; Nathan Evaniew; Michelle Ghert
Journal:  Am J Transl Res       Date:  2014-01-15       Impact factor: 4.060

2.  A lung/liver-on-a-chip platform for acute and chronic toxicity studies.

Authors:  David Bovard; Antonin Sandoz; Karsta Luettich; Stefan Frentzel; Anita Iskandar; Diego Marescotti; Keyur Trivedi; Emmanuel Guedj; Quentin Dutertre; Manuel C Peitsch; Julia Hoeng
Journal:  Lab Chip       Date:  2018-12-04       Impact factor: 6.799

3.  Exploring the Pharmacokinetic/Pharmacodynamic Relationship of Relebactam (MK-7655) in Combination with Imipenem in a Hollow-Fiber Infection Model.

Authors:  Jin Wu; Fred Racine; Michael K Wismer; Katherine Young; Donna M Carr; Jing C Xiao; Ravi Katwaru; Qian Si; Paul Harradine; Mary Motyl; Pratik R Bhagunde; Matthew L Rizk
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

4.  Found in Translation: Maximizing the Clinical Relevance of Nonclinical Oncology Studies.

Authors:  Mary E Spilker; Xiaoying Chen; Ravi Visswanathan; Chandra Vage; Shinji Yamazaki; Gang Li; Judy Lucas; Erica L Bradshaw-Pierce; Paolo Vicini
Journal:  Clin Cancer Res       Date:  2016-08-22       Impact factor: 12.531

5.  Multi-organ system for the evaluation of efficacy and off-target toxicity of anticancer therapeutics.

Authors:  Christopher W McAleer; Christopher J Long; Daniel Elbrecht; Trevor Sasserath; L Richard Bridges; John W Rumsey; Candace Martin; Mark Schnepper; Ying Wang; Franz Schuler; Adrian B Roth; Christoph Funk; Michael L Shuler; James J Hickman
Journal:  Sci Transl Med       Date:  2019-06-19       Impact factor: 17.956

6.  Bridging the gap between in vitro and in vivo: Dose and schedule predictions for the ATR inhibitor AZD6738.

Authors:  Stephen Checkley; Linda MacCallum; James Yates; Paul Jasper; Haobin Luo; John Tolsma; Claus Bendtsen
Journal:  Sci Rep       Date:  2015-08-27       Impact factor: 4.379

7.  Modulation of doxorubicin cytotoxicity by resveratrol in a human breast cancer cell line.

Authors:  Abdel-Moneim M Osman; Hadeel M Bayoumi; Sameer E Al-Harthi; Zoheir A Damanhouri; Mohamed F Elshal
Journal:  Cancer Cell Int       Date:  2012-11-16       Impact factor: 5.722

8.  Developing Exposure/Response Models for Anticancer Drug Treatment: Special Considerations.

Authors:  D R Mould; A-C Walz; T Lave; J P Gibbs; B Frame
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-01-21

9.  Utility of a Novel Three-Dimensional and Dynamic (3DD) Cell Culture System for PK/PD Studies: Evaluation of a Triple Combination Therapy at Overcoming Anti-HER2 Treatment Resistance in Breast Cancer.

Authors:  Anusha Ande; Tanaya R Vaidya; Bao N Tran; Michael Vicchiarelli; Ashley N Brown; Sihem Ait-Oudhia
Journal:  Front Pharmacol       Date:  2018-05-01       Impact factor: 5.810

10.  A microfluidics platform for combinatorial drug screening on cancer biopsies.

Authors:  Federica Eduati; Ramesh Utharala; Dharanija Madhavan; Ulf Peter Neumann; Thomas Longerich; Thorsten Cramer; Julio Saez-Rodriguez; Christoph A Merten
Journal:  Nat Commun       Date:  2018-06-22       Impact factor: 14.919

View more
  5 in total

1.  A microfluidic system that replicates pharmacokinetic (PK) profiles in vitro improves prediction of in vivo efficacy in preclinical models.

Authors:  Dharaminder Singh; Sudhir P Deosarkar; Elaine Cadogan; Vikki Flemington; Alysha Bray; Jingwen Zhang; Ronald S Reiserer; David K Schaffer; Gregory B Gerken; Clayton M Britt; Erik M Werner; Francis D Gibbons; Tomasz Kostrzewski; Christopher E Chambers; Emma J Davies; Antonio Ramos Montoya; Jacqueline H L Fok; David Hughes; Kristin Fabre; Matthew P Wagoner; John P Wikswo; Clay W Scott
Journal:  PLoS Biol       Date:  2022-05-26       Impact factor: 9.593

2.  Tumour-on-chip microfluidic platform for assessment of drug pharmacokinetics and treatment response.

Authors:  Tudor Petreus; Elaine Cadogan; Gareth Hughes; Aaron Smith; Venkatesh Pilla Reddy; Alan Lau; Mark James O'Connor; Susan Critchlow; Marianne Ashford; Lenka Oplustil O'Connor
Journal:  Commun Biol       Date:  2021-08-24

Review 3.  Organ-on-a-Chip Platforms for Drug Screening and Delivery in Tumor Cells: A Systematic Review.

Authors:  Inês M Gonçalves; Violeta Carvalho; Raquel O Rodrigues; Diana Pinho; Senhorinha F C F Teixeira; Ana Moita; Takeshi Hori; Hirokazu Kaji; Rui Lima; Graça Minas
Journal:  Cancers (Basel)       Date:  2022-02-13       Impact factor: 6.639

4.  A Microphysiological Cell-Culturing System for Pharmacokinetic Drug Exposure and High-Resolution Imaging of Arrays of 3D Microtissues.

Authors:  Christian Lohasz; Jacqueline Loretan; Dario Sterker; Ekkehard Görlach; Kasper Renggli; Paul Argast; Olivier Frey; Marion Wiesmann; Markus Wartmann; Martin Rausch; Andreas Hierlemann
Journal:  Front Pharmacol       Date:  2021-12-21       Impact factor: 5.810

Review 5.  The Combination of Cell Cultured Technology and In Silico Model to Inform the Drug Development.

Authors:  Zhengying Zhou; Jinwei Zhu; Muhan Jiang; Lan Sang; Kun Hao; Hua He
Journal:  Pharmaceutics       Date:  2021-05-12       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.